Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation

Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation

Abstract: the acute disturbances of cerebral circulation incidence accounts for nearly 70-80% of all such diseases in population, while this annual rate in Russian health care is about 2,19 cases on 1000 individuals. Pharmacoeconomic evaluation of this pathology contributes to the improvement of app...

Full description

Bibliographic Details
Main Authors:	A. Yu. Kulikov, L. A. Komarov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	pharmacoeconomic analysis the acute disturbances of cerebral circulation сerebrolysin standard therapy cost-effectiveness analysis budget impact analysis health technology assessment cost analysis.
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/49

Similar Items

Pharmacoeconomic analysis of Cellex® in the treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-06-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of perampanel for resistance partial epilepsy
by: D. Yu. Belousov, et al.
Published: (2018-06-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019-04-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of naft idrofuryl in patients with chronic obliterating diseases of lower limb arteries
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Pharmacoeconomics of spastic cerebral palsy
by: R. I. Yagudina, et al.
Published: (2018-02-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2020-07-01)

Pharmacoeconomic evaluation of the ceftolosan + tasobactam in the treatment of complicated nosocomial intraabdominal infections
by: I. N. Dyakov, et al.
Published: (2019-10-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
by: M. B. Kubaeva, et al.
Published: (2017-08-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS
by: M. V. Protsenko
Published: (2015-03-01)

Pharmacoeconomic analysis of adjuvant use of zonisamide therapy resistant partial epilepsy in adults
by: D. Yu. Belousov, et al.
Published: (2018-06-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01)

Pharmacoeconomic analysis of cost-benefit in evaluating the effectiveness of treatment for epilepsy in adults
by: P. N. Vlasov, et al.
Published: (2010-06-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: A. U. Kulikov, et al.
Published: (2015-03-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia
by: A. E. Cheberda, et al.
Published: (2018-06-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Pharmacoeconomic evaluation of aspirin therapy in pharmaceutical prevention of the first acute myocardial infarction in patients with stable angina
by: A. Yu. Kulikov, et al.
Published: (2010-02-01)

Clinical and economic analysis of macrocyclic gadolinium-based compounds for use in magnetic resonance imaging diagnostics
by: A. E. Cheberda, et al.
Published: (2020-01-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomics expediency of application of the combined preparation of Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of monopreparations
by: S. K. Zyryanov, et al.
Published: (2018-06-01)

Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment
by: A. U. Kulikov, et al.
Published: (2015-03-01)

CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA
by: Elena Albertovna Sobko, et al.
Published: (2015-09-01)

Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: Pharmacoeconomic aspects
by: V V Riazhenov, et al.
Published: (2014-02-01)

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01)